2247. Real-world Experience with Meropenem–Vaborbactam (M/V) for Treatment of Carbapenem-Resistant Enterobacteriaceae (CRE) Infections

BACKGROUND: M/V demonstrates in vitro activity against KPC-producing CRE, but real-world clinical experience is limited. METHODS: Patients treated for > 48 hours with M/V for CRE infections were included. Success was defined as improved symptoms, absence of recurrent infection, and survival at 30...

Descripción completa

Detalles Bibliográficos
Autores principales: Shields, Ryan K, McCreary, Erin K, Marini, Rachel V, Kline, Ellen G, Jones, Chelsea E, Hao, Binghua, Clancy, Cornelius J, Nguyen, Minh-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810515/
http://dx.doi.org/10.1093/ofid/ofz360.1925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810515/
http://dx.doi.org/10.1093/ofid/ofz360.1925

Ejemplares similares